Self-amplifying RNA or RNA replicon is a form of nucleic acid-based vaccine derived from
either positive-strand or negative-strand RNA viruses. The gene sequences encoding …

Self-amplifying RNA (SAM) represents a versatile tool that can be used to develop potent
vaccines, potentially able to elicit strong antigen-specific humoral and cellular-mediated …

The mRNA technology has emerged as a rapid modality to develop vaccines during
pandemic situations with the potential to protect against endemic diseases. The success of …

messenger RNA (mRNA)-based vaccines combine the positive attributes of both live-
attenuated and subunit vaccines. In order for these to be applied for clinical use, they require …

Despite more than two decades of research and development on nucleic acid vaccines,
there is still no commercial product for human use. Taking advantage of the recent …

There has been increased interest in the development of RNA-based vaccines for protection
against various infectious diseases and also for cancer immunotherapies. Rapid and cost …

The therapeutic potential for messenger RNA (mRNA) in infectious diseases and cancer
was first realized almost three decades ago, but only in 2018 did the first lipid nanoparticle …

mRNA vaccines elicit a potent immune response including antibodies and cytotoxic T cells.
mRNA vaccines are currently evaluated in clinical trials for cancer immunotherapy …

Advances in RNA technology during the past two decades have led to the construction of
replication-competent RNA, termed replicons, RepRNA, or self-amplifying mRNA, with high …

The recent clinical success of multiple mRNA-based SARS-CoV-2 vaccines has proven the
potential of RNA formulated in lipid nanoparticles (LNPs) in humans, and products based on …